463 related articles for article (PubMed ID: 33802957)
1. Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms.
Yeh SJ; Hsu BJ; Chen BS
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802957
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
3. Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications.
Lin YC; Chen BS
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142321
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Reprogramming and Landscape of Transcriptomic Interactions: Impending Therapeutic Interference of Triple-Negative Breast Cancer in Molecular Medicine.
Ray SK; Mukherjee S
Curr Mol Med; 2022; 22(10):835-850. PubMed ID: 34872474
[TBL] [Abstract][Full Text] [Related]
5. Multiple-Molecule Drug Design Based on Systems Biology Approaches and Deep Neural Network to Mitigate Human Skin Aging.
Yeh SJ; Lin JF; Chen BS
Molecules; 2021 May; 26(11):. PubMed ID: 34073305
[TBL] [Abstract][Full Text] [Related]
6. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
[TBL] [Abstract][Full Text] [Related]
7. Systems Drug Design for Muscle Invasive Bladder Cancer and Advanced Bladder Cancer by Genome-Wide Microarray Data and Deep Learning Method with Drug Design Specifications.
Su PW; Chen BS
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430344
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic virotherapy armed with an engineered interfering lncRNA exhibits antitumor activity by blocking the epithelial mesenchymal transition in triple-negative breast cancer.
Ang L; Guo L; Wang J; Huang J; Lou X; Zhao M
Cancer Lett; 2020 Jun; 479():42-53. PubMed ID: 32200038
[TBL] [Abstract][Full Text] [Related]
9. MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer.
Mathe A; Scott RJ; Avery-Kiejda KA
Int J Mol Sci; 2015 Nov; 16(12):28347-76. PubMed ID: 26633365
[TBL] [Abstract][Full Text] [Related]
10. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
[TBL] [Abstract][Full Text] [Related]
11. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
12. LncRNA LUCAT1 facilitates tumorigenesis and metastasis of triple-negative breast cancer through modulating miR-5702.
Mou E; Wang H
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31399501
[TBL] [Abstract][Full Text] [Related]
13. Systems Medicine Design based on Systems Biology Approaches and Deep Neural Network for Gastric Cancer.
Yeh SJ; Chen BS
IEEE/ACM Trans Comput Biol Bioinform; 2022; 19(5):3019-3031. PubMed ID: 34232888
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the Genome-Wide Genetic and Epigenetic Networks for Drug Discovery Based on Systems Biology Approaches in Colorectal Cancer.
Yeh SJ; Chen SW; Chen BS
Front Genet; 2020; 11():117. PubMed ID: 32211020
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance and Applications in Human Triple-Negative Breast Cancer.
Ding L; Gu H; Xiong X; Ao H; Cao J; Lin W; Yu M; Lin J; Cui Q
Cells; 2019 Nov; 8(12):. PubMed ID: 31766744
[TBL] [Abstract][Full Text] [Related]
17. Drug Target Identification and Drug Repurposing in Psoriasis through Systems Biology Approach, DNN-Based DTI Model and Genome-Wide Microarray Data.
Zhan YP; Chen BS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373186
[TBL] [Abstract][Full Text] [Related]
18. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
Narrandes S; Huang S; Murphy L; Xu W
BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
[TBL] [Abstract][Full Text] [Related]
19. Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.
Ting CT; Chen BS
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409008
[TBL] [Abstract][Full Text] [Related]
20. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
Wahdan-Alaswad R; Harrell JC; Fan Z; Edgerton SM; Liu B; Thor AD
Cell Cycle; 2016; 15(8):1046-59. PubMed ID: 26919310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
